Publication: Outcomes of mycophenolate mofetil vs. intravenous cyclophosphamide in induction therapy of childhood- onset lupus nephritis
Issued Date
2020-08-01
Resource Type
ISSN
01252208
Other identifier(s)
2-s2.0-85089944446
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Journal of the Medical Association of Thailand. Vol.103, No.8 (2020), 785-790
Suggested Citation
Suwannee Wisanuyotin, Anirut Pattaragarn, Ankanee Chanakul, Adisorn Lumpaopong, Wattana Chartapisak Outcomes of mycophenolate mofetil vs. intravenous cyclophosphamide in induction therapy of childhood- onset lupus nephritis. Journal of the Medical Association of Thailand. Vol.103, No.8 (2020), 785-790. doi:10.35755/jmedassocthai.2020.08.11180 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/59208
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Outcomes of mycophenolate mofetil vs. intravenous cyclophosphamide in induction therapy of childhood- onset lupus nephritis
Abstract
© JOURNAL OF THE MEDICAL ASSOCIATION OF THAILAND. Background: Intravenous cyclophosphamide (IVCY) concomitant with corticosteroids demonstrated better outcomes in therapy of proliferative lupus nephritis albeit adverse effects may occur. Mycophenolate mofetil (MMF) is a newer oral medication for treating lupus nephritis. Objective: To compare renal outcomes between IVCY and MMF in conjunction with corticosteroid for induction therapy of proliferative lupus nephritis. Materials and Methods: The authors reviewed the medical records from four university hospitals of children who received prednisolone with either MMF or IVCY for induction therapy of proliferative lupus nephritis between 2005 and 2014 in the present retrospective cohort study. Results: Twenty-eight and 85 patients were included in the MMF and IVCY group, respectively. The respective mean age at MMF and IVCY initiation was 12.36±2.87 and 11.84±3.04 years. Renal remission was not significantly different between the groups (p=0.690). Non-nephrotic range proteinuria (adjusted OR 2.93, 95% CI 1.23 to 6.94, p=0.015), and high initial GFR (adjusted OR 2.93, 95% CI 1.14 to 7.56, p=0.026) were significantly associated with achieving renal remission. Both infectious (82.1%) and non-infectious complications (96.9%) were more common in the IVCY group. Neither death nor end-stage renal disease (ESRD) occurred during the induction therapy. Conclusion: There was no significant difference in renal remission whether children received MMF or IVCY for induction therapy of lupus nephritis; however, adverse events occurred less frequently in the MMF group.